TransMedics Group (NASDAQ:TMDX) Price Target Lowered to $109.00 at Needham & Company LLC

TransMedics Group (NASDAQ:TMDX) had its price objective reduced by stock analysts at Needham & Company LLC from $208.00 to $109.00 in a note issued to investors on Tuesday, Briefing.com reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price objective would suggest a potential downside of 13.66% from the stock’s current price.

TMDX has been the subject of several other research reports. Oppenheimer lifted their price objective on TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, August 1st. Canaccord Genuity Group raised their price objective on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Piper Sandler reiterated an “overweight” rating and issued a $180.00 target price on shares of TransMedics Group in a research report on Monday, October 7th. Baird R W raised TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Finally, Robert W. Baird began coverage on TransMedics Group in a report on Tuesday, September 24th. They set an “outperform” rating and a $200.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $164.40.

TransMedics Group Price Performance

TransMedics Group stock opened at $126.24 on Tuesday. The business has a fifty day moving average price of $147.58 and a 200-day moving average price of $140.19. The firm has a market capitalization of $4.21 billion, a P/E ratio of 3,156.00 and a beta of 1.99. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. TransMedics Group has a one year low of $36.42 and a one year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The firm had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. During the same period in the prior year, the firm posted ($0.03) earnings per share. The company’s revenue for the quarter was up 117.7% on a year-over-year basis. As a group, equities research analysts forecast that TransMedics Group will post 1.22 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total value of $1,144,623.75. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,180,642.53. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other TransMedics Group news, Director James R. Tobin sold 20,000 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the completion of the sale, the director now directly owns 173,146 shares in the company, valued at approximately $27,587,352.18. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,180,642.53. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 64,205 shares of company stock valued at $9,981,907. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors have recently modified their holdings of TMDX. Amalgamated Bank grew its stake in shares of TransMedics Group by 6.7% in the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after acquiring an additional 70 shares during the period. Pitcairn Co. boosted its stake in shares of TransMedics Group by 1.5% in the 1st quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock worth $398,000 after buying an additional 78 shares during the last quarter. Harbour Capital Advisors LLC grew its holdings in shares of TransMedics Group by 1.7% in the third quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after acquiring an additional 81 shares during the period. Signaturefd LLC increased its position in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after acquiring an additional 93 shares during the last quarter. Finally, Arizona State Retirement System lifted its holdings in TransMedics Group by 2.1% in the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after acquiring an additional 186 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.